secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2024-10-02T23:59:59+00:00
Accession:  0001104659-24-105182
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia expands L606 license to Europe/Japan; gets nebulizer rights; $3.5M upfront, up to $157.75M milestones
--------------------------------------------------------------------------------

- Expanded exclusive license to include Europe, Japan, and other key markets outside North America; $3.5M upfront payment.
- Up to $157.75M in additional milestone payments: $7.75M development + $150M commercial sales milestones outside North America.
- Obtained exclusive rights to Pharmosa's next-generation smart-technology nebulizers for use with L606.
- L606 pivotal study in PH-ILD expected to start later this year; positive EMA scientific advice received.
- Open-label safety study shows L606 tolerated up to 378 mcg twice daily; supports twice-daily dosing via breath-actuated nebulizer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465924105182/0001104659-24-105182-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465924105182/tm2425377d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-105182

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer